Vanda Pharmaceuticals (VNDA)
(Real Time Quote from BATS)
$4.66 USD
-0.29 (-5.86%)
Updated Sep 19, 2024 11:37 AM ET
4-Sell of 5 4
C Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VNDA 4.66 -0.29(-5.86%)
Will VNDA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VNDA
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Other News for VNDA
4 stocks to watch on Thursday: DRI, FDX and more
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
Vanda slips as FDA rejects therapy for stomach condition
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids